Novo Nordisk A/S $NVO Stock Holdings Raised by JCIC Asset Management Inc.

JCIC Asset Management Inc. raised its stake in Novo Nordisk A/S (NYSE:NVO) by 29.9% in the 3rd quarter, HoldingsChannel reports. The firm owned 72,923 shares of the company’s stock after acquiring an additional 16,784 shares during the quarter. Novo Nordisk A/S makes up 1.1% of JCIC Asset Management Inc.’s portfolio, making the stock its 26th biggest position. JCIC Asset Management Inc.’s holdings in Novo Nordisk A/S were worth $2,765,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Scarborough Advisors LLC bought a new position in shares of Novo Nordisk A/S during the 1st quarter worth about $26,000. Root Financial Partners LLC bought a new stake in Novo Nordisk A/S in the 3rd quarter valued at about $32,000. Continuum Advisory LLC bought a new stake in Novo Nordisk A/S in the 2nd quarter valued at about $38,000. Latitude Advisors LLC bought a new stake in Novo Nordisk A/S in the 3rd quarter valued at about $38,000. Finally, Markowski Investments acquired a new position in Novo Nordisk A/S during the 2nd quarter worth approximately $43,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a report on Friday, October 9th. Cfra downgraded Novo Nordisk A/S from a “hold” rating to a “sell” rating and set a $38.00 price objective for the company. in a report on Tuesday, September 22nd. Berenberg Bank restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, September 21st. Weiss Ratings lowered Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, October 8th. Finally, Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. Five research analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and five have assigned a Sell rating to the company. According to data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Hold” and a consensus target price of $59.44.

Novo Nordisk A/S Stock Up 5.0%

Shares of NYSE NVO opened at $42.21 on Thursday. The stock has a market capitalization of $188.45 billion, a P/E ratio of 10.32, a P/E/G ratio of 1.36 and a beta of 0.70. The company has a 50-day moving average price of $40.84 and a 200-day moving average price of $44.07. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $64.16. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.66.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 58.61%. The company had revenue of $11.98 billion during the quarter. On average, equities research analysts forecast that Novo Nordisk A/S will post 3.42 EPS for the current fiscal year.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo beat analysts’ estimates for third-quarter earnings and revenue. Adjusted sales rose 4%, adjusted operating profit increased 27%, and obesity-drug sales climbed 22%. The company raised its full-year 2026 sales and operating-profit outlook. Reuters report on earnings and guidance
• Positive Sentiment: Wegovy pill sales exceeded Wall Street expectations, giving Novo a promising early foothold in the oral weight-loss drug market and helping drive the outlook upgrade. CEO Mike Doustdar said the launch had exceeded expectations. BioPharma Dive report on Wegovy pill sales
• Neutral Sentiment: Doustdar declined to provide 2027 guidance, leaving investors without a clear view of growth beyond this year. Novo’s CFO Karsten Munk Knudsen is also expected to leave the company. Article on earnings, outlook and 2027 guidance
• Negative Sentiment: Pricing pressure and weaker diabetes performance remain risks to growth, while impairment charges weighed on reported operating profit. Competition from Eli Lilly also remains a concern, especially as the oral obesity-drug market develops. Zacks analysis of earnings and risks

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.